Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX )

23.27 +0.01 (+0.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 954,589
Open 23.26
Bid (Size) 23.06 (4)
Ask (Size) 24.00 (152)
Prev. Close 23.26
Today's Range 22.84 - 23.35
52wk Range 13.49 - 24.49
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why NASDAQ:CPRX qualifies as a high growth stock.
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.
Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued. 
Via Chartmill

Performance

YTD
+8.13%
+8.13%
1 Month
+2.15%
+2.15%
3 Month
+11.77%
+11.77%
6 Month
+16.41%
+16.41%
1 Year
+68.75%
+68.75%

More News

Read More
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Exploring NASDAQ:CPRX's high growth characteristics.
Via Chartmill
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
Via Benzinga
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:CPRX: good value for what you're paying.
Via Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Via Chartmill
Unlocking the high Growth Potential of NASDAQ:CPRX.
Via Chartmill
NASDAQ:CPRX, an undervalued stock with good fundamentals.
Via Chartmill
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
NASDAQ:CPRX, a growth stock which is not overvalued.
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.